SynapDx is an early stage laboratory services company developing a blood based test to enable earlier detection of Autism Spectrum Disorders (ASDs). ASDs are characterized by impairment in language and socialization as well as restricted and repetitive behaviors. ASDs affect 1 in 88 children according to the Centers for Disease Control.
The average age of diagnosis is 4.5 years, yet age of first concern is 19 months. Early diagnosis leads to early treatment – and early treatment is believed to yield better outcomes. Today, ASDs are diagnosed using a variety of assessments that combine direct patient observation and medical history. The addition of a clinically meaningful blood test could hasten the diagnostic process and help children at risk for ASDs get access to the right evaluations earlier – and end up with better outcomes as they grow.
SynapDx's approach measures RNA gene expression differences, which current research suggests can distinguish between people with ASDs and those without. SynapDx is in the process of conducting additional studies to validate this approach.